AAstraZeneca Read More ESC 2026: AstraZeneca’s oral relaxin agonist succeeds in Phase II trialSeptember 1, 2026 AstraZeneca’s oral relaxin agonist improved cardiac function in patients with chronic heart failure in a Phase IIb trial.…